lung
transplant
treatment
option
patient
advanc
lung
diseas
irrevers
pulmonari
failur
despit
advanc
surgic
techniqu
lung
preserv
immunosuppress
manag
ischemiareperfus
injuri
infect
acut
chronic
allograft
reject
continu
major
problem
incid
sever
acut
reject
lung
transplant
exce
solid
organ
transplant
chronic
reject
commonli
call
bronchiol
obliteran
syndrom
bo
lead
caus
death
beyond
first
year
post
lung
transplant
key
clinic
featur
bo
develop
airway
obstruct
reduct
forc
expiratori
volum
second
respond
bronchodil
tabl
hallmark
histolog
find
chronic
reject
oblit
bronchiol
ob
inflammatori
process
affect
small
noncartilagen
airway
figur
repres
typic
find
ob
histopatholog
develop
bo
rare
within
first
year
lung
transplant
cumul
incid
rang
within
first
five
year
transplant
diagnosi
bo
typic
made
clinic
physiolog
radiograph
paramet
due
sporad
patchi
involv
ob
patholog
diagnosi
miss
transbronchi
biopsi
tbb
often
perform
exclud
diagnos
includ
acut
reject
infect
histolog
earli
lesion
bo
demonstr
submucos
lymphocyt
inflamm
disrupt
epithelium
small
airway
follow
ingrowth
fibromyxoid
granul
tissu
airway
lumen
result
partial
complet
obstruct
subsequ
granul
tissu
organ
cicatrici
pattern
result
fibrosi
thu
obliter
airway
lumen
instanc
residu
histolog
evid
bo
ring
circumferenti
elastin
around
otherwis
undetect
airway
term
vanish
airway
diseas
result
histolog
variabl
intern
societi
heart
lung
transplant
ishlt
develop
standard
nomenclatur
made
distinct
document
ob
bo
ad
hoc
work
group
establish
auspic
ishlt
purpos
develop
clinic
applic
system
publish
origin
recommend
group
conclud
reliabl
consist
indic
allograft
dysfunct
exclud
identifi
caus
adopt
term
bo
describ
dysfunct
recogn
may
may
patholog
evid
ob
present
group
also
defin
stage
bo
subcategori
indic
whether
patholog
evid
ob
identifi
clinic
cours
bo
vari
insidi
onset
gradual
declin
pulmonari
function
month
year
abrupt
onset
sever
declin
pulmonari
function
week
clinic
diagnosi
bo
requir
sustain
pulmonari
declin
reduc
week
exclus
acut
allograft
reject
anastomot
complic
strictur
infect
diseas
affect
pulmonari
function
comparison
acut
allograft
reject
defin
perivascular
peribronchi
mononuclear
inflamm
may
associ
acut
reduct
pulmonari
function
clinic
present
acut
allograft
reject
may
vari
asymptomat
patient
acut
reject
found
surveil
biopsi
nonspecif
symptom
includ
cough
dyspnea
sputum
product
fever
hypoxia
adventiti
sound
lung
auscult
current
classif
bo
base
chang
maximum
posttranspl
assign
predict
valu
mean
two
best
postop
valu
least
week
measur
reduct
mean
forc
expiratori
flow
middl
half
forc
vital
capac
use
earli
marker
bo
potenti
bo
current
ishlt
classif
system
bo
outlin
tabl
current
radiograph
imag
use
diagnost
tool
transplant
recipi
evalu
bo
howev
high
resolut
comput
tomographi
hrct
imag
inspiratori
expiratori
view
may
help
consid
diagnosi
numer
abnorm
may
seen
includ
hyperluc
airtrap
bronchiectasi
thicken
septal
line
mosaic
pattern
attenu
treeinbud
pattern
obtain
expiratori
ct
scan
may
help
reveal
airtrap
evid
inspiratori
scan
bo
furthermor
extent
airtrap
may
correl
bo
sever
acut
reject
well
defin
primari
risk
factor
develop
bo
recurr
late
sever
episod
acut
reject
associ
increas
risk
bo
moreov
hachem
et
al
recent
demonstr
singl
episod
minim
acut
reject
without
recurr
progress
higher
grade
reject
signific
predictor
bo
independ
risk
factor
pneumonia
andor
airway
colon
gram
posit
gram
neg
pathogen
well
fungi
independ
determin
chronic
allograft
dysfunct
interest
studi
serolog
chlamydia
pneumonia
donor
recipi
associ
develop
bo
lung
transplant
recipi
fact
bo
occur
frequent
earlier
c
pneumonia
seroposit
donor
revers
true
seroneg
recipi
anoth
studi
colon
lower
airway
aspergillu
also
determin
potenti
caus
role
develop
bo
postlung
transplant
exud
bronchiol
determin
hrct
imag
associ
increas
risk
bo
lung
transplant
recipi
type
transplant
whether
singl
bilater
may
risk
factor
develop
bo
retrospect
review
lung
transplant
recipi
chronic
obstruct
pulmonari
diseas
copd
bilater
transplant
recipi
like
free
bo
singl
recipi
three
year
vs
five
year
vs
transplant
p
lower
respiratori
tract
infect
due
commun
acquir
respiratori
virus
report
increas
risk
bo
includ
rhinoviru
coronaviru
respiratori
syncyti
viru
influenza
parainfluenza
human
metapneumoviru
human
herp
therefor
treatment
viral
infect
theoret
may
reduc
incid
bo
data
limit
cytomegaloviru
cmv
infect
also
well
describ
potenti
risk
factor
develop
bo
howev
one
studi
demonstr
histopatholog
confirm
cmv
pneumonia
treat
ganciclovir
risk
factor
bo
patient
surviv
particular
cmv
serolog
donorrecipi
group
treatment
cmv
subsequ
prevent
bo
remain
unclear
recent
studi
epsteinbarr
viru
ebv
reactiv
detect
repeat
ebv
dna
analysi
blood
lung
transplant
recipi
associ
develop
bo
ischemiareperfus
injuri
lung
transplant
primari
graft
dysfunct
associ
later
develop
bo
daud
et
al
report
lung
allograft
recipi
primari
graft
dysfunct
grade
grade
grade
multivari
model
demonstr
increas
risk
bo
primari
graft
dysfunct
independ
acut
reject
lymphocyt
bronchiti
communityacquir
respiratori
viral
infect
furthermor
increas
risk
bo
directli
relat
sever
primari
graft
dysfunct
gastroesophag
ge
reflux
common
postlung
transplant
may
contribut
chronic
allograft
reject
mechan
ge
reflux
contribut
bo
remain
unclear
presenc
bile
acid
pepsin
bronchoalveolar
lavag
bal
fluid
lung
transplant
recipi
suggest
aspir
may
elicit
airway
injuri
moreov
treatment
proton
pump
inhibitor
reduc
acid
reflux
affect
nonacid
reflux
includ
bile
pepsin
suggest
presenc
element
lower
airway
factor
associ
bo
earli
surgic
treatment
ge
reflux
fundopl
lung
transplant
associ
greater
freedom
bo
improv
surviv
singl
institut
studi
report
lung
transplant
recipi
abnorm
ambulatori
esophag
ph
probe
result
fundopl
patient
improv
bo
score
patient
longer
meet
criteria
bo
anoth
small
studi
demonstr
earli
aggress
surgic
treatment
ge
reflux
fundopl
improv
rate
bo
also
surviv
effect
human
leukocyt
antigen
hla
mismatch
upon
develop
bo
report
remain
controversi
develop
antihla
class
ii
antibodi
associ
bo
furthermor
associ
bo
mismatch
locu
two
dr
mismatch
total
mismatch
locu
b
locu
dr
locu
report
howev
mismatch
hla
locu
b
locu
associ
acut
cellular
reject
bo
research
need
investig
import
issu
emerg
concept
regard
bo
possibl
autoimmun
rather
alloimmun
hidden
epitop
collagen
type
v
epitop
expos
result
ischemia
reperfus
injuri
insult
may
damag
respiratori
epithelium
research
ongo
investig
import
find
small
number
studi
assess
differ
therapeut
modal
reportedli
benefici
patient
adjust
immunosuppress
therapi
use
immunomodul
medic
potenti
therapeut
option
adjust
immunosuppress
agent
demonstr
posit
outcom
cairn
et
al
report
convers
cyclosporin
tacrolimu
stabil
spirometr
measur
patient
bo
whyte
et
al
demonstr
similar
result
introduct
mycophenol
mofetil
one
studi
bo
less
like
progress
sirolimu
substitut
azathioprin
lung
transplant
recipi
receiv
cyclosporin
tacrolimu
sirolimu
discontinu
due
side
effect
use
immunosuppress
therapi
novel
way
may
improv
outcom
bo
evolv
research
use
aerosol
cyclosporin
singlecent
random
doubleblind
placebocontrol
trial
aerosol
cyclosporin
perform
initi
drug
within
six
week
lung
transplant
along
routin
system
immunosuppress
aerosol
cyclosporin
improv
rate
acut
reject
improv
surviv
extend
period
chronic
rejectionfre
surviv
recent
singl
center
random
studi
demonstr
improv
pulmonari
function
lung
transplant
patient
receiv
aerosol
cyclosporin
first
year
transplant
compar
placebo
recent
case
report
demonstr
aerosol
tacrolimu
associ
improv
function
capac
oxygen
patient
bo
therapi
investig
includ
alemtuzumab
anticd
antibodi
significantli
improv
histolog
grade
bo
patient
impact
pulmonari
function
open
label
studi
azithromycin
display
immunomodulatori
effect
seem
benefici
sever
pulmonari
disord
includ
bo
three
studi
show
valu
prolong
azithromycin
mg
oral
everi
day
total
patient
bo
improv
patient
larger
observ
studi
gottlieb
et
al
demonstr
patient
bo
improv
month
azithromycin
therapi
respond
improv
month
therapi
univari
analysi
azithromycin
respond
month
demonstr
higher
pretreat
bal
neutrophil
neurohr
et
al
also
demonstr
bal
neutrophilia
stabl
lung
transplant
recipi
predict
valu
identif
bo
statin
coenzym
reductas
inhibitor
wide
use
lipid
lower
agent
demonstr
immunomodulatori
effect
surviv
lung
transplant
recipi
receiv
statin
therapi
much
greater
patient
statin
therapi
acut
reject
less
frequent
found
statin
group
none
recipi
start
statin
therapi
first
postop
year
develop
ob
wherea
cumul
incid
among
control
subject
evid
extracorpor
photopheresi
effect
method
treatment
inflammatori
disord
tcell
depend
includ
bo
late
two
studi
demonstr
stabil
airway
obstruct
due
bo
extracorpor
photopheresi
patient
patient
respect
without
complic
occur
procedur
fact
salerno
et
al
report
patient
histolog
revers
reject
function
stabil
observ
patient
bo
accompani
slight
increas
stabil
number
peripher
blood
high
cell
vitro
featur
treg
cell
nonrespons
patient
bo
show
declin
peripher
treg
subset
anim
studi
confirm
cell
appear
play
key
role
immunomodulatori
effect
extracorpor
photopheresi
period
one
studi
report
patient
bo
treat
extracorpor
photopheresi
signific
improv
declin
mlmonth
therapi
mlmonth
cycl
therapi
p
effect
extracorpor
photopheresi
absolut
group
patient
signific
therapi
toler
recent
lung
transplant
recipi
experienc
reduct
rate
declin
lung
function
associ
progress
bo
extracorpor
photopheresi
therapi
declin
month
prior
treatment
extracorpor
photopheresi
mlmonth
slope
decreas
mlmonth
period
initi
therapi
mean
differ
rate
declin
mlmonth
p
furthermor
actual
improv
patient
start
extracorpor
photopheresi
mean
increas
mlmonth
import
therapeut
strategi
treat
bo
initi
prevent
aggress
treatment
known
associ
factor
well
earli
identif
bo
order
immedi
begin
avail
therapi
initi
clinic
manag
patient
focu
risk
reduct
primari
graft
dysfunct
decreas
mechan
ventil
time
donor
reduc
allograft
ischemia
time
also
limit
cardiopulmonari
bypass
blood
product
transfus
transplant
routin
screen
defin
onset
bo
import
appear
therapeut
window
treatment
option
avail
jain
et
al
demonstr
azithromycin
treatment
initi
develop
bo
stage
independ
associ
signific
reduct
risk
death
thu
clinician
close
monitor
lung
transplant
recipi
care
monitor
earli
chronic
reject
spirometri
perform
routin
lung
transplant
recipi
look
chang
measur
base
ishlt
classif
system
tabl
use
hrct
imag
inspiratori
expiratori
view
chest
assess
airtrap
may
help
base
initi
studi
research
less
conclus
regard
valu
current
radiograph
imag
remain
support
diagnost
evalu
manag
bo
figur
demonstr
use
hrct
imag
diagnos
bo
yearold
patient
underw
right
singl
lung
transplant
defici
suddenli
develop
reduct
year
undergo
singl
left
lung
transplant
bo
right
allograft
clearli
signific
bronchiectasi
due
longstand
bo
recent
allograft
left
side
sign
bronchiectasi
airtrap
support
diagnosi
bo
allograft
aggress
treatment
ge
reflux
avoid
infect
time
vaccin
instrument
manag
lung
transplant
recipi
experiment
risk
factor
report
bo
consid
clinic
standpoint
evalu
transplant
recipi
includ
higher
bronchoalveolar
bal
neutrophilia
level
well
airway
colon
pseudomona
aeruginosa
research
need
better
defin
clinic
role
evolv
factor
definit
treatment
bo
result
bronchiectasi
retransplant
howev
lung
retransplant
remain
controversi
due
limit
organ
avail
lower
surviv
rate
compar
initi
transplant
novick
et
al
review
record
patient
underw
retransplant
bo
north
american
european
center
cohort
actuari
surviv
rate
month
year
year
postop
survivor
aliv
year
retransplant
studi
larger
cohort
retranspl
recipi
retranspl
recipi
demonstr
similar
surviv
statist
although
surviv
rate
lung
retransplant
lower
surviv
rate
initi
transplant
lung
retransplant
continu
perform
recipi
develop
bo
recent
surviv
rate
lung
retransplant
improv
retrospect
cohort
studi
patient
underw
lung
retransplant
januari
may
unit
state
demonstr
surviv
surviv
surviv
author
assess
outcom
patient
undergo
retransplant
specif
bo
definit
improv
outcom
patient
lung
retransplant
modern
era
moreov
smaller
studi
address
surviv
lung
retransplant
bo
adult
patient
tabl
outlin
research
studi
publish
sinc
recent
studi
report
surviv
rate
respect
comparison
current
unadjust
surviv
rate
initi
transplant
year
year
publish
christi
et
al
lung
transplant
recipi
bo
remain
primari
caus
mortal
first
year
current
lung
alloc
score
era
lung
transplant
recipi
significantli
fewer
bosfre
day
followup
research
need
better
defin
pathophysiolog
mechan
bo
order
either
prevent
delay
onset
disord
therapi
avail
bo
current
limit
serv
slow
declin
pulmonari
function
lung
retransplant
continu
controversi
surviv
rate
improv
patient
bo
past
decad
thu
consid
treatment
option
patient
popul
list
abbrevi
use
manuscript
alphabet
order
bo
bronchiol
obliteran
syndrom
bal
bronchoalveolar
copd
chronic
obstruct
pulmonari
diseas
cmv
cytomegaloviru
ebv
epsteinbarr
viru
forc
expiratori
flow
middl
half
forc
vital
capac
forc
expiratori
volum
second
ge
gastroesophag
hrct
high
resolut
comput
tomographi
ishlt
intern
societi
heart
lung
transplant
ob
oblit
bronchiol
tbb
transbronchi
biopsi
author
declar
compet
interest
author
manuscript
complet
literatur
review
develop
manuscript
without
assist
contributor
prepar
develop
manuscript
fund
requir
complet
work
